Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial von Coles, Alasdair J, Dr, Twyman, Cary L, MD, Arnold, Douglas L, Prof, Cohen, Jeffrey A, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Miller, Tamara, MD, Fisher, Elizabeth, PhD, Sandbrink, Rupert, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Oyuela, Pedro, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial von Cohen, Jeffrey A, Prof, Coles, Alasdair J, PhD, Arnold, Douglas L, Prof, Confavreux, Christian, Prof, Fox, Edward J, MD, Hartung, Hans-Peter, Prof, Havrdova, Eva, Prof, Selmaj, Krzysztof W, Prof, Weiner, Howard L, Prof, Fisher, Elizabeth, PhD, Brinar, Vesna V, MD, Giovannoni, Gavin, Prof, Stojanovic, Miroslav, MD, Ertik, Bella I, MD, Lake, Stephen L, ScD, Margolin, David H, MD, Panzara, Michael A, MD, Compston, D Alastair S, Prof

Volltext

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings von Coles, Alasdair J, Cohen, Jeffrey A, Fox, Edward J, Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W, Traboulsee, Anthony, Compston, D. Alastair S, Margolin, David H, Thangavelu, Karthinathan, Chirieac, Madalina C, Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J, Panzara, Michael A, Arnold, Douglas L

Volltext

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study von Connick, Peter, MRCP, Kolappan, Madhan, MRCP, Crawley, Charles, FRCP, Webber, Daniel J, PhD, Patani, Rickie, MRCP, Michell, Andrew W, PhD, Du, Ming-Qing, Prof, Luan, Shi-Lu, PhD, Altmann, Daniel R, PhD, Thompson, Alan J, Prof, Compston, Alastair, Prof, Scott, Michael A, PhD, Miller, David H, Prof, Chandran, Siddharthan, Prof

Volltext

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy von Havrdova, Eva, Arnold, Douglas L, Cohen, Jeffrey A, Hartung, Hans-Peter, Fox, Edward J, Giovannoni, Gavin, Schippling, Sven, Selmaj, Krzysztof W, Traboulsee, Anthony, Compston, D. Alastair S, Margolin, David H, Thangavelu, Karthinathan, Rodriguez, Claudio E, Jody, Darlene, Hogan, Richard J, Xenopoulos, Panos, Panzara, Michael A, Coles, Alasdair J

Volltext

Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations von Pfeffer, Gerald, Burke, Ailbhe, Yu-Wai-Man, Patrick, Compston, D. Alastair S, Chinnery, Patrick F

Volltext

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223 von Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.

Volltext

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis von Thompson, Sara A. J., Jones, Joanne L., Cox, Amanda L., Compston, D. Alastair S., Coles, Alasdair J.

Volltext

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study von Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S

Volltext

Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis von Hill-Cawthorne, Grant A, Button, Tom, Tuohy, Orla, Jones, Joanne L, May, Karen, Somerfield, Jennifer, Green, Alison, Giovannoni, Gavin, Compston, D Alastair S, Fahey, Michael T, Coles, Alasdair J

Volltext

Bayesian refinement of association signals for 14 loci in 3 common diseases von Maller, Julian B, McVean, Gilean, Byrnes, Jake, Vukcevic, Damjan, Palin, Kimmo, Su, Zhan, Howson, Joanna M M, Auton, Adam, Myers, Simon, Morris, Andrew, Pirinen, Matti, Brown, Matthew A, Burton, Paul R, Caulfield, Mark J, Compston, Alastair, Farrall, Martin, Hall, Alistair S, Hattersley, Andrew T, Hill, Adrian V S, Mathew, Christopher G, Pembrey, Marcus, Satsangi, Jack, Stratton, Michael R, Worthington, Jane, Craddock, Nick, Hurles, Matthew, Ouwehand, Willem, Parkes, Miles, Rahman, Nazneen, Duncanson, Audrey, Todd, John A, Kwiatkowski, Dominic P, Samani, Nilesh J, Gough, Stephen C L, McCarthy, Mark I, Deloukas, Panagiotis, Donnelly, Peter

Volltext

Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years von Oh, Jiwon, Achiron, Anat, Celius, Elisabeth G., Chambers, Christina, Derwenskus, Joy, Devonshire, Virginia, Hellwig, Kerstin, Hutton, George J., McCombe, Pamela, Moore, Marie, Rog, David, Schneider, Jean-Raphael, Simm, Renata Faria, Sousa, Livia, Vincent, Stephen G., Chung, Luke, Daizadeh, Nadia, Mitchell, Colin, Compston, D. Alastair S.

Volltext

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients von Giovannoni, Gavin, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Havrdova, Eva, Selmaj, Krzysztof W, Margolin, David H, Lake, Stephen L, Kaup, Susan M, Panzara, Michael A, Compston, D. Alastair S

Volltext

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial von Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.

Volltext

The philosopher of the nervous system von Compston, Alastair

Volltext

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis von Cox, Amanda L., Thompson, Sara A. J., Jones, Joanne L., Robertson, Vicki H., Hale, Geoff, Waldmann, Herman, Compston, D. Alastair S., Coles, Alasdair J.

Volltext

Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation von Jones, Joanne L., Thompson, Sara A. J., Loh, Priscilla, Davies, Jessica L., Tuohy, Orla C., Curry, Allison J., Azzopardi, Laura, Hill-Cawthorne, Grant, Fahey, Michael T., Compston, Alastair, Coles, Alasdair J.

Volltext

Transcript specific regulation of expression influences susceptibility to multiple sclerosis von Ban, Maria, Liao, Wenjia, Baker, Amie, Compston, Alastair, Thorpe, John, Molyneux, Paul, Fraser, Mary, Khadake, Jyoti, Jones, Joanne, Coles, Alasdair, Sawcer, Stephen

Volltext

Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci von De Jager, Philip L, Jia, Xiaoming, Wang, Joanne, de Bakker, Paul I W, Ottoboni, Linda, Aggarwal, Neelum T, Piccio, Laura, Raychaudhuri, Soumya, Tran, Dong, Aubin, Cristin, Briskin, Rebeccah, Romano, Susan, Baranzini, Sergio E, McCauley, Jacob L, Pericak-Vance, Margaret A, Haines, Jonathan L, Gibson, Rachel A, Naeglin, Yvonne, Uitdehaag, Bernard, Matthews, Paul M, Kappos, Ludwig, Polman, Chris, McArdle, Wendy L, Strachan, David P, Evans, Denis, Cross, Anne H, Daly, Mark J, Compston, Alastair, Sawcer, Stephen J, Weiner, Howard L, Hauser, Stephen L, Hafler, David A, Oksenberg, Jorge R

Volltext

Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells von Smets, Ide, Fiddes, Barnaby, Garcia-Perez, Josselyn E, He, Di, Mallants, Klara, Liao, Wenjia, Dooley, James, Wang, George, Humblet-Baron, Stephanie, Dubois, Bénédicte, Compston, Alastair, Jones, Joanne, Coles, Alasdair, Liston, Adrian, Ban, Maria, Goris, An, Sawcer, Stephen

Volltext